TCRT (Alaunos Therapeutics) Cyclically Adjusted FCF per Share: $-42.93 (As of Mar. 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.12
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Cyclically Adjusted FCF per Share?

Alaunos Therapeutics TCRT +1.92% 28 Cyclically Adjusted FCF per Share is $-42.93 as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Alaunos Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.529. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-42.93 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 9.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 11.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Alaunos Therapeutics was 54.60% per year. The lowest was -0.30% per year. And the median was 12.40% per year.

As of today (2026-07-06), Alaunos Therapeutics's current stock price is $2.12. Alaunos Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-42.93. Alaunos Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Alaunos Therapeutics  (NAS:TCRT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Alaunos Therapeutics Cyclically Adjusted FCF per Share Related Terms


Alaunos Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Cyclically Adjusted FCF per Share Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -72.36 -59.19 -49.18 -43.64 -44.63

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.52 -41.08 -48.54 -44.63 -42.93

TCRT vs DRMA, MBIO, ELAB: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Alaunos Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alaunos Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Alaunos Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Alaunos Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.529/330.2130*330.2130
=-0.529

Current CPI (Mar. 2026) = 330.2130.

Alaunos Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -17.460 241.018 -23.922
201609 -16.461 241.428 -22.515
201612 -15.110 241.432 -20.666
201703 -16.803 243.801 -22.759
201706 -17.201 244.955 -23.188
201709 -13.634 246.819 -18.241
201712 -13.254 246.524 -17.753
201803 -20.348 249.554 -26.925
201806 -11.064 251.989 -14.499
201809 -9.220 252.439 -12.061
201812 -11.594 251.233 -15.239
201903 -9.563 254.202 -12.423
201906 -7.606 256.143 -9.805
201909 -9.704 256.759 -12.480
201912 -9.773 256.974 -12.558
202003 -7.822 258.115 -10.007
202006 -12.328 257.797 -15.791
202009 -12.739 260.280 -16.162
202012 -14.649 260.474 -18.571
202103 -11.241 264.877 -14.014
202106 -16.314 271.696 -19.828
202109 -6.956 274.310 -8.374
202112 -10.821 278.802 -12.816
202203 -5.442 287.504 -6.250
202206 -5.753 296.311 -6.411
202209 -4.295 296.808 -4.778
202212 -4.863 296.797 -5.411
202303 -5.909 301.836 -6.465
202306 -4.463 305.109 -4.830
202309 -3.984 307.789 -4.274
202312 -4.613 306.746 -4.966
202403 -1.197 312.332 -1.266
202406 -1.051 314.175 -1.105
202409 -0.488 315.301 -0.511
202412 -0.370 315.605 -0.387
202503 -0.482 319.799 -0.498
202506 -0.418 322.561 -0.428
202509 -0.387 324.800 -0.393
202512 -0.237 324.054 -0.242
202603 -0.529 330.213 -0.529

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-42.93 mean?
Alaunos Therapeutics (TCRT) has a Cyclically Adjusted FCF per Share of $-42.93 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Cyclically Adjusted FCF per Share too high?
Alaunos Therapeutics' current Cyclically Adjusted FCF per Share is $-42.93. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Cyclically Adjusted FCF per Share compare to DRMA and MBIO?
Alaunos Therapeutics' Cyclically Adjusted FCF per Share of $-42.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Cyclically Adjusted FCF per Share is $-42.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.12 — trading 211.8% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-42.93. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Cyclically Adjusted FCF per Share is $-42.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.12 is trading 211.8% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Cyclically Adjusted FCF per Share: $-42.93
  • GF Value™: $0.68 vs. price of $2.12 (211.8% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.12
Price
$0.68
GF Value